Eltrombopag Dose Adjustment During Reactive Secondary Thrombocytosis in patient with ITP

Autor:	Mohanad A. Ahmed, Elabbass Abdelmahmuod, Elrazi Awadelkarim A Ali, Mohamed A. Yassin
Rok vydání:	2020
Předmět:	medicine.medical_specialty business.industry Eltrombopag Secondary thrombocytosis Gastroenterology chemistry.chemical_compound Reactive thrombocytosis chemistry Dose adjustment Internal medicine Medicine Platelet In patient business
DOI:	10.22541/au.160438331.13299327/v1
Popis:	Eltrombopag is relatively new drug used in Thrombocytopenia. Its dose should be adjusted based on platelets count. It should be stopped when platelets count reach 400,000/mm³. Here, we share our case report of stopping Eltrombopag based on platelets increment in secondary reactive thrombocytosis irrespective of Eltrombopag treatment.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::cae065766f2999c8a6466cda98e1afce https://doi.org/10.22541/au.160438331.13299327/v1 Zobrazit plný text záznamu